AI and Brand Strategy for Pharma Research — PharmaMatrix
A research-led brand and digital experience for an oncology development company. The work connects a complex scientific programme with the people who need to understand it, using an AI Guide and purpose-built media resources within the wider site project.
The Mandate
Make PharmaMatrix's research understandable without flattening the science or overstating the evidence. Build a credible public introduction and an audience-aware digital experience that supports informed conversations with the research team.
The Challenge
An investigational cancer programme cannot be marketed like an established product. Its communications must explain the scientific rationale while keeping early findings separate from demonstrated clinical benefit. Confidence depends as much on the boundaries of the claim as on the strength of the story.
A journalist needs a usable explanation and attributable material. A researcher needs scientific depth. A prospective study participant needs clear, restrained information and a route to the clinical team. One generic company page cannot serve those needs equally well.
The Strategic Approach
The positioning starts with the research proposition: 'A new class of selective oncology therapeutics.' It introduces the programme through its scientific origin and directs readers toward the ASCO abstract and registered clinical trial rather than relying on promotional assertions.
The wider digital project treats the website as an informed conversation, not just a brochure. Dedicated audience resources and the PharmaMatrix Guide provide different ways into the same scientific programme, while human contact remains available for questions requiring clinical judgement or authorized company comment.
The Company and Its Research Programme
PharmaMatrix is an Edmonton-based, clinical-stage oncology research and development company advancing CCI-001, a novel colchicine derivative and microtubule disruptor. Its scientific foundations include computational chemistry associated with Dr. Jack Tuszynski's research at the University of Alberta.
Bladder cancer is a lead research focus. The registered PMH-001 Phase I protocol, NCT04823897, studies CCI-001 in recurrent or metastatic solid tumours, both as monotherapy and in combination with standard chemotherapy. CCI-001 remains investigational; it is not an approved treatment.
Breast cancer is an emerging expansion direction supported by preclinical research, not an established clinical indication. The development programme also explores other solid tumours. These are research opportunities, not claims of proven benefit for patients.
An AI Guide Built Around the Audience
The PharmaMatrix project includes an AI agent called Guide. It is designed to help journalists and media professionals understand the company and locate press resources, while giving researchers and clinicians a deeper way to explore the mechanism, publications and trial design.
For prospective study participants and their families, the experience uses plain language and provides a trial pre-screening pathway. It supports preparation for a conversation with the clinical team; it does not diagnose, recommend treatment or decide whether a patient is eligible.
The agent's supporting architecture includes scientific knowledge retrieval and conversation context. Its instructions distinguish preclinical evidence from clinical findings, restrict confidential material and provide human escalation for appropriate requests. Those safeguards are design requirements, not a guarantee that every AI answer is correct.
Media Resources That Support Accurate Coverage
The wider site project includes a dedicated media page and a branded media kit. A downloadable press package brings together a press release and company fact sheet, with a plain-language CCI-001 backgrounder and reusable company boilerplate.
The media experience separates public facts from material requiring authorization. Journalists have a route to request interviews or attributable comment, rather than treating AI-generated wording as an authorized company quotation.
Built for the Next Stage
PharmaMatrix has a live public website introducing its oncology programme, linking to the ASCO abstract and registered clinical trial, and providing a direct inquiry route. The wider digital experience includes the AI Guide and specialized audience resources.
The broader platform is designed to grow with the programme, accommodating new public research and deeper audience resources as they become available. Scientific development plans include further trial evaluation and potential expansion into breast cancer. Timing and scope depend on evidence, funding and regulatory progress; no launch date or clinical outcome is promised here.
The Work to Date
The public-facing introduction connects PharmaMatrix's scientific proposition with independent research references and a direct inquiry route. The wider project adds an intelligent engagement layer and media resources to support more substantive conversations as the site expands.
This case study documents positioning and digital experience work. It does not claim measured patient recruitment, investment raised, commercial growth or treatment efficacy. The next communications test is whether clearer understanding produces appropriate, informed inquiries.